Two additional AML patients achieve remission in Cohort 2 of RAINIER trial; 90% response rate

Aptevo Therapeutics Inc.

Two additional AML patients in Cohort 2 of RAINIER trial achieved remission within 30 days of treatment.
Overall 9 of 10 frontline AML patients achieved remission with mipletamig + ven/aza triplet, vs 66% doublet benchmark.
Complete remission rate (CR) of 70% with triplet outperforms 36% CR from Viale-A ven/aza only study.
No cytokine release syndrome (CRS) observed in RAINIER trial to date; all remissions ongoing.
Cohort 2 enrollment nearing completion; six patients planned at 18 mcg dose level.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.